P131 International Benchmarking on Psoriasis Pharmacoepidemiology: Epidemiology, Etiologies, Symptoms, Treatment and Prevention

Abstract Psoriasis which can involve the skin, nails and joints, is classified by the World Health Organisation as chronic, painful, disfiguring and disabling non communicable disease (NCD) for which there is no specific and definitive cure.1 Why Psoriasis is very difficult to treat? It is like this, because, it looks like many skin diseases at the same time,2 with no specific clinical aspects and many factory interacting together: Environmental, Psychological, Immunological, Genetic and Physiological. As a result, the therapeutic solution will be difficult in most clinical cases and will take time for a definitive recovery. This lead us to prepare an international Benchmarking on Psoriasis Pharmacoepidemiology: Epidemiology, Etiologies, Symptoms, Treatment and Prevention. Despite Of Corticosteroids, which are the best medicine for many diseases all over the world, there are other medicines to use Therefore, scientists have been fighting for so many years, to find new medicines and therapeutic protocols especially natural ones, using herbs and nutritional methods to treat Psoriasis. This study will give us an holistic overview from the theoretical recovery guarentees of varied treatments in different countries worldwide (using Argan oil in Morocco, using Vitamin d in France,...) to the Pratical recovery ­constraints.

Publication Details

Journal
British Journal of Dermatology
Published
2024-12-01
DOI
https://doi.org/10.1093/bjd/ljae360.161
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P131 International Benchmarking on Psoriasis Pharmacoepidemiology: Epidemiology, Etiologies, Symptoms, Treatment and Prevention

British Journal of Dermatology
Health Systems, Economic Evaluations, Quality of Life
article

P131 International Benchmarking on Psoriasis Pharmacoepidemiology: Epidemiology, Etiologies, Symptoms, Treatment and Prevention

article en

Abstract

Abstract Psoriasis which can involve the skin, nails and joints, is classified by the World Health Organisation as chronic, painful, disfiguring and disabling non communicable disease (NCD) for which there is no specific and definitive cure.1 Why Psoriasis is very difficult to treat? It is like this, because, it looks like many skin diseases at the same time,2 with no specific clinical aspects and many factory interacting together: Environmental, Psychological, Immunological, Genetic and Physiological. As a result, the therapeutic solution will be difficult in most clinical cases and will take time for a definitive recovery. This lead us to prepare an international Benchmarking on Psoriasis Pharmacoepidemiology: Epidemiology, Etiologies, Symptoms, Treatment and Prevention. Despite Of Corticosteroids, which are the best medicine for many diseases all over the world, there are other medicines to use Therefore, scientists have been fighting for so many years, to find new medicines and therapeutic protocols especially natural ones, using herbs and nutritional methods to treat Psoriasis. This study will give us an holistic overview from the theoretical recovery guarentees of varied treatments in different countries worldwide (using Argan oil in Morocco, using Vitamin d in France,...) to the Pratical recovery ­constraints.

British Journal of DermatologyVol. 191(Supplement_3)
Openalex Percentile: Top 72%
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.